Tag

WBVR
October 10, 2023

CEPI to invest up to $25.9 million, with support from the EU, in trials in East Africa to assess a vaccine candidate against Rift Valley Fever (RVF) in people most at risk of infection

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its partnership with Wageningen Bioveterinary Research (WBVR) to advance WBVR’s vaccine candidate against Rift Valley fever (RVF) through a multi-site Phase...
Read More
,
August 24, 2022

LARISSA consortium reaches milestone: Novel Rift Valley fever vaccine dosed in Phase I human trial

The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA[1] consortium and which started this week, will assess...
Read More
August 5, 2019

CEPI awards contract worth up to US$12.5 million to consortium led by Wageningen Bioveterinary Research to develop a human vaccine against Rift Valley fever

Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new partnering agreement. With support from the European Union’s...
Read More
,